These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 28894357)

  • 1. Advances in the delivery of buprenorphine for opioid dependence.
    Rosenthal RN; Goradia VV
    Drug Des Devel Ther; 2017; 11():2493-2505. PubMed ID: 28894357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine implants in medical treatment of opioid addiction.
    Chavoustie S; Frost M; Snyder O; Owen J; Darwish M; Dammerman R; Sanjurjo V
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):799-807. PubMed ID: 28571505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series.
    Soyka M; Groß G
    Am J Drug Alcohol Abuse; 2021 Sep; 47(5):599-604. PubMed ID: 34407703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New developments in managing opioid addiction: impact of a subdermal buprenorphine implant.
    Itzoe M; Guarnieri M
    Drug Des Devel Ther; 2017; 11():1429-1437. PubMed ID: 28546740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update.
    Soyka M
    Pharmacopsychiatry; 2021 Jan; 54(1):18-22. PubMed ID: 33212514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
    Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
    Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical removal of extended-release buprenorphine depot due to adverse reactions.
    Burton A; DeBona DJ; Handzel M; Kelly-Pisciotti S; Qiao M; Rojek D; Acquisto NM
    Am J Emerg Med; 2024 Jul; 81():127-128. PubMed ID: 38723364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Remission of Opioid Use Disorder in an Adolescent Using Buprenorphine Extended - Release Subcutaneous Injection: A Case Report.
    Schmuhl KK; Golec A; Ebersole AM
    J Adolesc Health; 2024 Jul; 75(1):200-202. PubMed ID: 38402472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
    Saulle R; Vecchi S; Gowing L
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011983. PubMed ID: 28447766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder.
    Tompkins CNE; Neale J; Strang J
    J Subst Abuse Treat; 2019 Sep; 104():64-71. PubMed ID: 31370986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal buprenorphine patch: Potential for role in management of opioid dependence.
    Dhawan A; Modak T; Sarkar S
    Asian J Psychiatr; 2019 Feb; 40():88-91. PubMed ID: 30772733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations when prescribing opioid agonist therapies for people living with HIV.
    Tarfa A; Lier AJ; Shenoi SV; Springer SA
    Expert Rev Clin Pharmacol; 2024 Jul; 17(7):549-564. PubMed ID: 38946101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
    Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
    JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-monthly subcutaneous buprenorphine (Sublocade) for opioid use disorder.
    Med Lett Drugs Ther; 2018 Feb; 60(1541):35-37. PubMed ID: 29485976
    [No Abstract]   [Full Text] [Related]  

  • 15. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication Treatment of Opioid Use Disorder.
    Bell J; Strang J
    Biol Psychiatry; 2020 Jan; 87(1):82-88. PubMed ID: 31420089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder.
    Walsh SL; Comer SD; Zdovc JA; Sarr C; Björnsson M; Strandgården K; Hjelmström P; Tiberg F
    Neuropsychopharmacology; 2024 May; 49(6):1050-1057. PubMed ID: 38200140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine.
    Vorspan F; Hjelmström P; Simon N; Benyamina A; Dervaux A; Brousse G; Jamain T; Kosim M; Rolland B
    Expert Opin Drug Deliv; 2019 Sep; 16(9):907-914. PubMed ID: 31364884
    [No Abstract]   [Full Text] [Related]  

  • 19. Update on pharmacotherapy for treatment of opioid use disorder.
    Ayanga D; Shorter D; Kosten TR
    Expert Opin Pharmacother; 2016 Dec; 17(17):2307-2318. PubMed ID: 27734745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.